PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 22, 2024Expert Opinion on Investigational Drugs2 citationsOpen Access

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian Adults: results from a phase 1, randomized, open-label trial

View Full Paper
YLYingxin LiJNJoo Young NaYZYunting Zhu

Key Points

Key points are not available for this paper at this time.

Abstract

This Phase 1 trial was planned to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single dose of riliprubart in healthy East-Asian adult participants.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e5b5efb6db64358754e664https://doi.org/10.1080/13543784.2024.2394186
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey2024 · 18 citations
  2. 2First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor2023 · 20 citations
  3. 3Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study2023 · 1 citations
  4. 4Ultrastructural mechanisms of macrophage-induced demyelination in CIDP2018 · 108 citations
  5. 5Complement System in Brain Architecture and Neurodevelopmental Disorders2020 · 110 citations